Novel indoloquinoline derivative, IQDMA, suppresses STAT5 phosphorylation and induces apoptosis in HL-60 cells

Chemico-Biological Interactions

Volumn 176, Issue 1, 2008, Pages 40-47

  Chien, Ching Ming ^a   Yang, Sheng Huei ^a   Lin, Kuei Li ^a   Chen, Yeh Long ^a   Chang, Long Sen ^b   Lin, Shinne Ren ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

HL 60 cells; IL 6; IQDMA; Src; STAT5

Indexed keywords

CYCLIN D1; INDOLOQUINOLINE DERIVATIVE; INTERLEUKIN 6; N (11H INDOLO[3,2 C]QUINOLIN 6 YL) N,N DIMETHYLETHANE 1,2 DIAMINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT5 PROTEIN; STEROID RECEPTOR COACTIVATOR 1; SURVIVIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DOWN-REGULATION; ENZYME ACTIVATION; HL-60 CELLS; HUMANS; INDOLES; INTERLEUKIN-6; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUINOLINES; STAT5 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 52949135888     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.06.008     Document Type: Article

References (29)

1. Battle T.E., and Frank D.A. The role of STATs in apoptosis. Curr. Mol. Med. 2 (2002) 381-392
2. Yu H., and Jove R. The STATs of cancer: new molecular targets come of age. Nat. Rev. Cancer 4 (2004) 97-105
3. Moriggl R., Sexl V., and Kenner L. STAT5 tetramer formation is associated with leukemogenesis. Cancer Cell 7 (2005) 87-99
4. Debierre-Grockiego F. Anti-apoptotic role of STAT5 in haematopoietic cells and in the pathogenesis of malignancies. Apoptosis 9 (2004) 717-728
5. Baskiewicz-Masiuk M., and Machalinski B. The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AMl cells. Eur. J. Haematol. 72 (2004) 420-429
6. Kawano M., Hirano T., and Matsuda T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 (1988) 83-85
7. Klejman A., Schreiner S.J., Nieborowska-Skoreska M., Slupianek A., Wilson M., Smithgall T.E., and Skoroski T. The Src family kinase Hck couples Bcr/Abl to STAT5 activation in myeloid leukemia cells. EMBO J. 21 (2002) 5766-5774
8. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23 (2004) 8017-8023
9. Gesbert F., and Griffin J.D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 96 (2000) 2269-2276
10. Magne S., Caron S., Charon M., Rouyez M.C., and Dusanter-Fourt I. STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol. Cell Biol. 23 (2003) 8934-8945
11. Nam S., Williams A., Vulture A., List A., Bhalla K., Smith D., Lee F.Y., and Jove R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 6 (2007) 1400-1405
12. Levy D.E., and Darnell J.E. STATs: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002) 651-662
13. Song H., Sondak V.K., Barber D.L., Reid T.J., and Lin J. Modulation of Janus kinase 2 by cisplatin in cancer cells. Int. J. Oncol. 24 (2004) 1017-1026
14. Michael J.P. Quinoline, quinazoline and acridone alkaloids. Nat. Prod. Rep. 14 (1997) 11-20
15. Balasubramanian M., and Keay J.G. Pyridines and Their Benzo Derivatives: Applications (1996), Pergamon Press, New York
16. Deady L.W., Kaye A.J., Finlay G.J., Baguley B.C., and Denny W.A. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J. Med. Chem. 40 (1997) 2040-2046
17. Fortune J.M., Velea L., Graves D.E., Utsugi T., Yamada Y., and Osheroff N. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Biochemistry 38 (1999) 15580-15586
18. Chen Y.L., Chung C.H., Chen I.L., Chen P.H., and Jeng H.Y. Synthesis and cytotoxic activity evaluation of indolo-, pyrrolo-, and benzofuro-quinolin-2(1H)-ones and 6-anilinoindoloquinoline derivatives. Bioorg. Med. Chem. 10 (2002) 2705-2712
19. Lin Y.H., Yang S.H., Chien C.M., Hu X.W., Huang Y.H., Lu C.M., Chen Y.L., and Lin S.R. Induction of G2/M phase arrest and apoptosis by a novel indoloquinoline derivative, IQDMA, in K562. Cells Drug Dev. Res. 67 (2006) 743-751
20. Hu X.W., Chien C.M., Yang S.H., Lin Y.H., Lu C.M., Chen Y.L., and Lin S.R. A novel indoloquinoline derivative, IQDMA, induces S-phase arrest and apoptosis in promyelocytic leukemia HL-60 cells. Cell Biol. Toxicol. 22 (2006) 417-427
21. Bowman T., Garcia R., Turkson J., and Jove R. STATs in oncogenesis. Oncogene 19 (2000) 2474-2488
22. L and Bcl-2 on mitochondria in human B cells. Eur. J. Immunol. 35 (2005) 971-976
23. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem. J. 374 (2003) 1-20
24. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4 (2004) 11-22
25. Manabe N., Kubota Y., Kitanaka A., Ohnishi H., Taminato T., and Tanaka T. Src transduces signaling via growth hormone (GH)-activated GH receptor (GHR) tyrosine-phosphorylating GHR and STAT5 in human leukemia cells. Leuk. Res. 30 (2006) 1391-1398
26. Oltersdorf T., Elmore S.W., and Shoemaker A.R. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
27. L signal pathway. Ann. Hematol. 85 (2006) 443-449
28. Frankel A.E., and Gill P.S. VEGF and myeloid leukemias. Leuk. Res. 28 (2004) 675-677
29. Bellamy W.T., Richter L., Frutiger Y., and Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59 (1999) 728-733